Core Viewpoint - The lawsuit involving Jianyuan Trust has been accepted by the Shanghai High People's Court, with the case number (2025) Hu Min Zhong 419, and the trial has not yet commenced [1] Group 1: Lawsuit Details - The company is the respondent in the appeal, with Shanghai Dongfang Securities Asset Management Co., Ltd. as the plaintiff [1] - The amount in dispute is 402 million yuan [1] - The Shanghai Financial Court previously dismissed the claims made by Dongfang Asset Management in the first instance, leading to the appeal [1] Group 2: Company Actions - The company will actively exercise its litigation rights in accordance with the law [1] - It is currently not possible to assess the impact of the lawsuit on the company's profits for the current or future periods [1]

Group 1 - The core point of the article highlights the financing activities of Jianyuan Trust, which recorded a financing purchase amount of 0.24 billion yuan on August 19, ranking 962nd in the two markets [1] - Over the last three trading days from August 15 to August 19, Jianyuan Trust received financing purchases of 0.27 billion yuan, 0.29 billion yuan, and 0.24 billion yuan respectively [1] - On the same day, the company experienced a securities lending activity with a sell-off of 20.93 thousand shares, resulting in a net sell-off of 15.37 thousand shares [1]

Core Viewpoint - Qianhong Pharmaceutical has reached a settlement with Jianyuan Trust to recover half of its investment in the "Chuangying 51" trust plan after a five-year dispute, highlighting the ongoing challenges faced by companies in managing trust investments and the impact of external economic conditions on asset performance [2][3][4]. Group 1: Settlement Details - On August 14, Qianhong Pharmaceutical announced it had reached a settlement with Jianyuan Trust regarding the "Chuangying 51" trust plan, resulting in a one-time payment of 56.9943 million yuan, which will be recognized as approximately 48.45 million yuan in profit for the 2025 fiscal year [2][5]. - The total investment in the two trust products purchased in 2018 amounted to 340 million yuan, with both products experiencing overdue payments [3][4]. - The settlement allows Qianhong to retain part of the trust beneficiary rights, indicating a strategy to balance risk while recovering some capital [6]. Group 2: Background of Trust Products - The "Chuangying 51" trust plan was set to mature on December 29, 2019, while the "Ruiying 64" plan was due on August 15, 2019, but both faced overdue payments due to the underlying assets' lack of liquidity and the borrower's financial difficulties [3][4]. - The total amount involved in the lawsuits against Jianyuan Trust was approximately 376.1866 million yuan, with overdue principal totaling 340 million yuan [4]. Group 3: Industry Context - The trend of companies facing challenges with trust investments is not isolated, as evidenced by other firms like Hengyin Technology and Chengdu Road and Bridge, which have also reported significant overdue amounts from trust products [7]. - The current economic environment has led to a preference for lower-risk fixed-income products among listed companies, with 36 companies reportedly investing a total of approximately 8.9 billion yuan in trust products since early 2025, reflecting a shift in investment strategy [7].

Core Viewpoint - Qianhong Pharmaceutical reached a settlement with Jianyuan Trust regarding a payment dispute from a trust plan purchased in 2018, resulting in a one-time payment of 56.9943 million yuan, which will contribute approximately 48.45 million yuan to the company's 2025 profit [1][4]. Group 1: Qianhong Pharmaceutical - Qianhong Pharmaceutical invested 170 million yuan in the "Anxin Chuangyin 51 Hao" trust plan, which was originally due on December 29, 2019 [4]. - After a prolonged legal battle lasting five years, the company agreed to withdraw its lawsuit in exchange for half of the remaining principal and earnings, amounting to 56.9943 million yuan [4]. - The expected profit increase of approximately 48.45 million yuan will be recorded in the 2025 profit statement [4]. Group 2: Jianyuan Trust - Jianyuan Trust reported a total revenue of 150 million yuan for the first half of 2025, marking an 84.89% year-on-year increase, and a net profit of 40 million yuan, up 13.36% [4][5]. - The company added 117 new trust projects in the first half of 2025, corresponding to a new trust scale of 1,080.01 billion yuan, reflecting a 785% year-on-year growth [5]. - As of June 30, 2025, Jianyuan Trust's managed trust assets reached 3,378.91 billion yuan, a 33.44% increase from the beginning of the year [5]. Group 3: Financial Performance and Business Development - In 2024, Jianyuan Trust achieved total revenue of 310 million yuan, with a net profit of 53 million yuan, representing a 25.15% year-on-year growth [7]. - The company’s solid business became a significant pillar, with interest income from proprietary business increasing by 12% to 32.5149 million yuan [7]. - Jianyuan Trust's trust asset management scale reached 2,532 billion yuan by the end of 2024, with a substantial growth of 78% from the beginning of the year [7].

Core Viewpoint - The announcement details the litigation progress of Jianyuan Trust Co., Ltd., including settlements and arbitration outcomes, which may impact the company's financials. Group 1: Litigation Status - One case has been settled and withdrawn, one arbitration ruling has been revoked, and one case has been withdrawn [2] - The company is a defendant in the settled and withdrawn cases, while it is the applicant in the revoked arbitration case [2] Group 2: Financial Implications - The settled case involved a litigation amount of 177.87 million yuan, the revoked arbitration case involved a principal amount of 10 million yuan, and the withdrawn case involved 365,600 yuan [2] - The company will recognize liabilities based on the settlement results for the settled case, and will reverse previously recognized liabilities for the revoked arbitration case [2][7] Group 3: Specific Case Details - In the case involving Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., a settlement agreement was signed on August 13, 2025, with the company paying 56.99 million yuan [3][4] - The company received a civil ruling allowing the withdrawal of the case, with the litigation costs borne by Changzhou Qianhong [4] Group 4: Other Litigation Developments - In the case involving Haoke Technology Co., Ltd., the company was ordered to return a trust principal of 10 million yuan, but the arbitration ruling was later revoked by the Shanghai Financial Court [5][6] - A separate case involving a natural person had its claim amount adjusted from 1.6 million yuan to 365,600 yuan [7]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Jianyuan Trust, which has a high rolling PE ratio of 506.58 times, significantly above the industry average of 48.52 times [1][2] - As of June 30, 2025, Jianyuan Trust has 86,323 shareholders, an increase of 12,051 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - For the first half of 2025, Jianyuan Trust reported a revenue of 150 million yuan, representing a year-on-year increase of 84.89%, and a net profit of approximately 40.29 million yuan, reflecting a year-on-year growth of 13.36% [1] Group 2 - Jianyuan Trust's main business includes proprietary and trust services, with its primary products being in these areas [1] - The company ranks 21st in terms of PE ratio within the diversified financial industry, which has a median PE of 29.68 times [1][2] - The total market capitalization of Jianyuan Trust is approximately 29.336 billion yuan [1][2]

建元信托股份有限公司公告 建元信托股份有限公司 诉讼进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏, 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、前期诉讼进展情况 （一）涉及常州千红生化制药股份有限公司的案件 公司前期于《诉讼公告暨前期诉讼进展公告》（编号：临 2020-006）中披露了 涉及常州千红生化制药股份有限公司（以下简称"常州千红制药公司"）的 1 宗案 件（案号为"（2020）沪 74 民初 3 号"，以下简称"本案"），该案件原告为常州 千红制药公司，被告为本公司，涉诉金额 17,786.94 万元。 2025 年 8 月 13 日，经双方友好协商，公司与常州千红制药公司签署《和解协 议》。根据《和解协议》（以下简称"本协议"），本协议签署当日，本公司向常 州千红制药公司支付和解款 5,699.43 万元；常州千红制药公司向上海金融法院提交 案件所处的诉讼阶段：1 宗案件已和解并撤诉，1 宗案件已撤销仲裁裁决，1 宗案件已撤诉。 建元信托股份有限公司（以下简称"公司"、"本公司"）所处的当事人地 位：已和解并撤诉案件、已撤诉案件 ...

Group 1 - The diversified financial sector increased by 0.38% on August 14, with Nanhua Futures leading the gains [1] - The Shanghai Composite Index closed at 3666.44, down 0.46%, while the Shenzhen Component Index closed at 11451.43, down 0.87% [1] - Key stocks in the diversified financial sector showed varied performance, with Nanhua Futures rising by 6.52% to a closing price of 24.52 [1] Group 2 - Major stocks that declined included Jiuding Investment, which fell by 9.98% to a closing price of 19.48 [2] - The overall net capital flow in the diversified financial sector showed a net inflow of 49.12 million yuan from main funds, while retail investors contributed a net inflow of 15.2 million yuan [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Lakala achieving a turnover of 3.774 billion yuan [1][2]

证券代码：002550 证券简称：千红制药 公告编号：2025-023 常州千红生化制药股份有限公司 关于与建元信托股份有限公司签署和解协议 暨诉讼进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 年年度报告》、《2020 年年度报告》 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）2018 年 购买了安信创赢 51 号·特定资产收益权集合资金信托计划（以下简称"创赢 51 号信托计划"）理财产品，到期时间为 2019 年 12 月 29 日。自 2019 年 12 月起， 该笔理财产品出现逾期未兑付，逾期本金 17,000 万元。公司就创赢 51 号信托计 划项下与建元信托股份有限公司（以下简称"建元信托"）的受益权转让协议纠 纷向上海金融法院提起诉讼，案号为（2020）沪 74 民初 3 号，法院受理时的涉 诉金额为 17,786.94 万元。具体情况详见公司披露的《2018 年年度报告》、 《2019 、《2021 年年度报告》、《2022 年年度报告》、 《2023 年年度报告》与《诉讼公告》（公告编号：2020-0 ...

公司动态 日前，建元信托最新发布的2025年半年报显示，公司在营业收入、利润以及信托规模等方面均取得显著增长，不过在存量风险化解和涉诉方面仍面临一定挑 战。 2025年上半年，建元信托经营业绩表现出色。营业总收入达1.5亿元，同比增长84.89%；实现归母净利润0.4亿元，同比增长13.36%。截至2025年6月末，公 司受托管理信托规模3378.91亿元，较年初增长33.44%。 其中，信托业务增速较快，1-6月建元信托实现信托业务收入1.13亿元，新增设立信托项目117个，对应新增信托规模1080.01亿元，同比增长785%。 尽管业绩向好，但建元信托在存量风险化解和涉诉方面仍面临诸多问题。 在保底承诺方面，截至2020年12月31日，建元信托存在尚未了结的提供保底承诺等事项金额共计752.76亿元。公司通过收回兜底文件、达成和解、兑付信托 利益等方式积极解决，截至本财务报表批准日，尚余保底承诺金额13.43亿元。 建元信托在半年报中表示，公司在解决保底承诺等事项过程中，全面深入自查后确认不存在未披露的保底承诺等事项，并已与控股股东上海砥安投资管理有 限公司就未能解决/尚未发现的保底承诺/原股东侵占影响达 ...